Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04383210 |
|
Recruitment Status :
Active, not recruiting
First Posted : May 12, 2020
Last Update Posted : February 14, 2023
|
Sponsor:
Elevation Oncology
Information provided by (Responsible Party):
Elevation Oncology
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Locally Advanced Solid Tumor Metastatic Solid Tumor Pancreatic Cancer Lung Cancer Head and Neck Cancer Breast Cancer Kidney Cancer Colorectal Cancer Bladder Cancer Ovarian Cancer Sarcoma Gallbladder Cancer Bile Duct Cancer Esophageal Cancer Uterine Cancer Cholangiocarcinoma Prostate Cancer | Drug: Seribantumab | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 75 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors |
| Actual Study Start Date : | September 29, 2020 |
| Estimated Primary Completion Date : | June 2023 |
| Estimated Study Completion Date : | June 2023 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Cholangiocarcinoma
MedlinePlus related topics:
Genes and Gene Therapy
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Cohort 1
A minimum of 55 adult advanced solid tumor patients harboring NRG1 gene fusions, who have received prior standard treatment, excluding prior ERBB-directed therapy. Seribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively. |
Drug: Seribantumab
Anti-HER3 monoclonal antibody |
|
Experimental: Cohort 2
Up to 10 adult advanced solid tumor patients harboring NRG1 gene fusions, who have received prior standard treatment, including prior ERBB-directed therapy. Seribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively. |
Drug: Seribantumab
Anti-HER3 monoclonal antibody |
|
Experimental: Cohort 3
Up to 10 adult advanced solid tumor patients harboring NRG1 gene fusions lacking an EGF-like domain, who have received prior standard treatment, which may have included prior ERBB-directed therapy. Seribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively. |
Drug: Seribantumab
Anti-HER3 monoclonal antibody |
Primary Outcome Measures :
- Objective Response Rate [ Time Frame: Up to 12 months ]The primary objective of this study is to determine the overall objective response rate (ORR) by independent radiologic review to single agent seribantumab in patients with NRG1 gene fusion positive advanced cancer according to RECIST 1.1
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
To be eligible for participation in the study, patients must meet the following inclusion criteria:
- Locally-advanced or metastatic solid tumor with an NRG1 gene fusion identified through molecular assays, such as PCR, NGS (RNA or DNA) or FISH, by a CLIA-certified or similarly accredited laboratory
- Availability of fresh or archived FFPE tumor sample to be submitted to a central laboratory for confirmation of NRG1 gene fusion status
- Patients should have received a minimum of one prior standard therapy appropriate for their tumor type and stage of disease, progressed or been nonresponsive to these available therapies, with no further available curative therapy options
- ≥ 18 years of age
- ECOG performance status (PS) 0, 1 or 2
- Patients must have at least one measurable extra-cranial lesion as defined by RECIST v1.1
- Adequate hepatic function defined as:
- Serum AST and serum ALT < 2.5 × upper limit of normal (ULN), or AST and ALT < 5 × ULN if liver function abnormalities due to underlying malignancy
- Total bilirubin < 2.0 ULN. Subjects with a known history of Gilberts Disease and an isolated elevation of indirect bilirubin are eligible
- Adequate hematologic status, defined as:
- Absolute neutrophil count (ANC) ≥1.5 × 109/L not requiring growth factor support for at least 7 days prior to Screening, and
- Platelet count ≥100.0×109/L not requiring transfusion support for at least 7 days prior to Screening
- Able to provide informed consent or have a legal representative able and willing to do so
- Ability to comply with outpatient treatment, laboratory monitoring, and required clinic visits for the duration of study participation
- Willingness of men and women of reproductive potential to observe conventional and effective birth control for the duration of treatment and for 3 months following study completion; this may include barrier methods such as condom or diaphragm with spermicidal gel.
Exclusion Criteria:
- Known, actionable oncogenic driver mutation other than NRG1 fusion where available standard therapy is indicated
- Life expectancy < 3 months
- Pregnant or lactating
- Prior treatment with ERBB3/HER3 directed therapy (Cohort 1 only)
- Prior treatment with pan-ERBB or any ERBB/HER2/HER3 directed therapy (Cohort 1 only)
- Symptomatic or untreated brain metastases (Note: Patients with asymptomatic brain metastases treated with radiation or surgery and without evidence of progression by imaging at screening are eligible to participate in the study. Patients requiring ongoing corticosteroids to treat brain metastases will not be eligible).
- Received other investigational agent or anticancer therapy within 28 days prior to planned start of seribantumab or 5 half-lives, whichever is shorter
- Prior to initiation of seribantumab treatment, patients must have recovered from clinically significant toxicities from prior anticancer or investigational therapy
- Any other active malignancy requiring systemic therapy
- Known hypersensitivity to any of the components of seribantumab or previous CTCAE grade 3 or higher hypersensitivity reactions to fully human monoclonal antibodies
- Clinically significant cardiac disease, including symptomatic congestive heart failure, unstable angina, acute myocardial infarction within 12 months of planned first dose, or unstable cardiac arrhythmia requiring therapy (including torsades de pointes)
- Active uncontrolled systemic bacterial, viral, or fungal infection
- Patients who are not appropriate candidates for participation in this clinical study for any other reason as deemed by the investigator
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04383210
Locations
Show 42 study locations
Sponsors and Collaborators
Elevation Oncology
| Responsible Party: | Elevation Oncology |
| ClinicalTrials.gov Identifier: | NCT04383210 |
| Other Study ID Numbers: |
ELVCAP-001-01 |
| First Posted: | May 12, 2020 Key Record Dates |
| Last Update Posted: | February 14, 2023 |
| Last Verified: | February 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
Keywords provided by Elevation Oncology:
|
NRG1 Neuregulin 1 Gene fusion |
Additional relevant MeSH terms:
|
Neoplasms Cholangiocarcinoma Gallbladder Neoplasms Bile Duct Neoplasms Uterine Neoplasms Urogenital Neoplasms Neoplasms by Site Genital Diseases Urogenital Diseases Digestive System Neoplasms Digestive System Diseases Genital Diseases, Female |
Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Neoplasms, Female Neoplasms by Histologic Type Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Biliary Tract Neoplasms Biliary Tract Diseases Gallbladder Diseases Bile Duct Diseases Uterine Diseases |